For oncologists, access to "organized wisdom" in a few clicks

Share this article:
For oncologists, access to "organized wisdom" in a few clicks
For oncologists, access to "organized wisdom" in a few clicks

A tool that launched on MedPageToday.com earlier this month promises to streamline the research process for physicians. Called the Oncology Next Tool, it can deliver patient-focused information just by inputting information with a few clicks. Anthony Manson, MedPage VP of strategic partnerships estimates it currently houses close to 5,000 pages of information about lung cancer alone.

Free access is currently being sponsored on MedPageToday.com by Boehringer Ingelheim, which has two lung cancer drugs in its pipeline but none on the market. The tool will expand beyond lung cancer to include breast, skin and colorectal cancers. A semi-exclusive license makes MedPage the only one of the big medical portals to host it.

Manson said the tool, which was built by CollabRx, amounts to “organized wisdom” that will make it easier for physicians to home in on treatments that could possibly extend patients' lives.

The interface is a simple one: physicians check off boxes such as cancer stage, metastases locations and screened biomarkers. The results include possible drug therapies, clinical trial information and the status of appropriate pipeline drugs. Results may also include recommendations for additional biomarker tests.

Manson said the tool's information is only going to grow as researchers identify more genetic flags that signal a particular cancer's characteristics. This means more information to tap into, and a few more boxes to check off for a more acute level of personalization.

As streamlined as the results appear, CollabRx,'s chief scientist Smruti Vidwans told MM&M that the simple user experience belies “a very complicated interplay between our internal science team and IT department.”

This consists of three primary information streams: an algorithm that scoops up drug, clinical trial and research information; an internal CollabRx team of PhD-trained residents that sifts this information; and oncology thought leaders who filter the algorithm and resident inputs, as well as offer their own spin on what's important in the field. All of this is then tagged and coded so that a physician's clicks bring up a patient-centric list of information and possible treatment options.

The tool also has a back-end benefit: Manson said that it doesn't just help doctors stay on top of the most relevant information, but that it also “gives us a lot of information behind their whole mindset and rationale,” thereby providing more insight as to what it means to think like a doctor.

Although Boehringer Ingelheim has two lung cancer drugs in its pipeline, Manson and Vidwans said sponsorship has no influence on the drug and clinical trial information that surfaces, nor does it determine the order in which information appears. “Church and state,” is how Manson described the setup.

The site is promoting the tool using email alerts and search engine optimization, along with additional traffic drivers within the site. MedPage will also be promoting the tool during the fall and spring conference season.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...